Member Info for elcap

Not looked in for a couple of days. Just noticed no Crazy! What gives?

Even better still. AP says the good news has not stopped yet, and is hopeful to have further news to report before the end of April. Bloody brilliant interview!!!!!!!!

about other companies on BB's but I have to this time. GR needs to watch link. This is how to run a company!!!!! http://www.proactiveinvestors.co.uk/companies/stocktube/9123/vast-resources-eyes-near-term-production-from-eureka-gold-mine-in-Zimbabwe

What are chances of a 2nd RNS re ROM GOV. Now that would put the icing on the cake!

Randomaxe - Your posts have made me chuckle. I too had that all to brief moment of excitement when the RNS popped up. Don't be posting anymore. I can't be take SP dropping again!! I bet Crazy wishes he had that skill.

I don't feel sorry for GR. The man's either extremely unlucky or inept. I still have hope that the quality of our assets will shine through and SP will get back to the .6's, .7's, even dare I say it 1p+. However I have zero faith in GR. That last move on VOX did it for me, when he said I will not be doing a placement TODAY, then did one 3 days later!!!! At present I would welcome a "For no reason at all AIM spike". Rant over. I very rarely even look at this BB anymore, its not worth it. All it is day after day the Crazy show. Has he not got anyone in the real world to talk to.

SAR to release RNS with info already provided in the SRRA. That would surely get price moving!!

The 2 RNS' released by SRRA are incredibly good news for us, Looks like the drugs DO work. (I knew the Verve were wrong).

27/02/2018 12:05pm PR Newswire (Canada) Sierra Oncology, Inc. (NASDAQ:SRRA) Intraday Stock Chart Today : Tuesday 27 February 2018 Click Here for more Sierra Oncology, Inc. Charts. - Ongoing SRA737 clinical studies expanded to target aggregate enrollment of 200 patients across ten cancer indications � - Adding new SRA737 monotherapy cohort for CCNE1-driven ovarian cancer - - SRA141 IND submission planned in H2 2018 - VANCOUVER, Feb. 27, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today reported significant progress in the advancement of its strategic pipeline of drug assets. The company announced noteworthy progress in the Dose Escalation Phase 1 portions for both of its ongoing Phase 1/2 clinical trials evaluating its potential best-in-class Chk1 inhibitor, SRA737. The company announced expansion of the efficacy-oriented Phase 2 portions of both trials, which will now target aggregate enrollment of approximately 200 patients across ten cancer indications. The company also announced it is planning to initiate a Phase 1b/2 clinical trial in the fourth quarter of 2018 that will evaluate SRA737 in combination with ZEJULA� (niraparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). In addition, the company announced it is planning to submit an Investigational New Drug (IND) for its Cdc7 inhibitor, SRA141, in the second half of 2018 in order to initiate a Phase 1/2 clinical trial, focused initially on the treatment of colorectal cancer. Sierra is hosting a Program Update event today at 10:00 am ET in New York where it will provide an update on the progress of its portfolio of assets, with specific reference to its clinical development program for SRA737. The Sierra management team will be joined by Dr. Udai Banerji, Chief Investigator for the company's ongoing SRA737 Phase 1/2 clinical trials, and Dr. Alan D'Andrea, a member of Sierra's DDR Advisory Committee. A live webcast of the event will be available at www.sierraoncology.com. "We are pleased to report encouraging progress in the advancement of both of our next generation DDR assets. In particular, SRA737 has demonstrated an emerging preclinical and clinical profile which appears competitively differentiated in comparison to other clinical stage Chk1 inhibitors, which gives us confidence to significantly expand its development program both as monotherapy and in a variety of combination settings," said Dr. Nick Glover, President and CEO of Sierra Oncology. "In support of this expansion, we are adding further clinical centers in 2018, with the goal of reporting preliminary clinical data in the fourth quarter of 2018." "The safety profile for SRA737 has been highly promising, both as monotherapy and in combination with low do

VANCOUVER, Feb. 27, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced the signing of a clinical supply agreement with Janssen Research & Development, LLC. (Janssen) for access to TESARO's ZEJULA� (niraparib), an orally administered poly (ADP-ribose) polymerase (PARP) inhibitor undergoing clinical development by Janssen for patients with prostate cancer. Sierra intends to evaluate its Chk1 inhibitor, SRA737, in combination with niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC). The scientific rationale for the combination was supported by translational research conducted at The Institute of Cancer Research, London. Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, will be the Chief Investigator of the new study. He noted: "I look forward to supporting Sierra's investigation of this combination. Research has demonstrated the potential benefit of PARP inhibitor therapy in prostate cancer patients with defects in HRR, and clinical trials are under way evaluating niraparib in these patients. However, the combination of Chk1 inhibition with PARP inhibition potentially may expand the application of niraparib to patients with HRR proficient tumors or re-sensitize patients who have developed PARP inhibitor resistance." "Preclinical studies have demonstrated synergy between PARP inhibitors and SRA737, including in contexts where PARP inhibitors have minimal activity such as HRR proficient and PARP inhibitor resistant settings," added Dr. Nick Glover, President and CEO of Sierra Oncology. "PARP inhibitors impede the repair of single-strand DNA breaks, resulting in stalled DNA replication forks and double strand breaks that make the cell highly reliant on HRR, which is regulated by Chk1. The combined inhibition of both pathways is the basis for Sierra's drug combination strategy of SRA737 with niraparib." "This supply agreement with Janssen is significant strategically in the continued advancement of SRA737 as it enables the exploration of a novel and independent development path for our Chk1 inhibitor, supported by both a promising scientific and a compelling commercial rationale," added Dr. Angie You, Chief Business & Strategy Officer and Head of Commercial at Sierra. Sierra plans to conduct an open-label, multicenter Phase 1b/2 dose-ranging study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of SRA737 in combination with niraparib in patients with mCRPC. The study is intended to determine the maximum tolerated dose and schedule of SRA737 in combination with niraparib and to propose a recommended Phase 2 dose

will see this rise quickly over .14. Come on people get buying!!!! GLA

To say LSE are useless!!!!!!!

Then a big push up. That's my prediction for today. GLA

Commenting today, Myles Campion, Executive Director of FCR, said: "This maiden resource estimate is an outstanding result for the Company and provides us with a strong platform to rapidly progress the project. The addition of silver represents a significant potential contribution to the overall project economics and as we progress our work I am sure its presence will impact favourably on financial models. 

Morning world! Very quiet today

Fingers crossed significant steps forward regarding getting the RTO have already been made. News in the next 2 weeks would be good. Have a good weekend all.

What warning will be get when we come out of suspension? Do they just issue a 7am RNS and we immediately start trading at 8am on the same day, or do they have to pre-warn the market before then? Appreciate your assistance in advance. Elcap

.13 on the bid and .15 on the ask. Shouldn't it be showing 0.00 on both?

Trading on AIM for the under-mentioned securities has been temporarily suspended from 13/10/2017 7:30am pursuant to AIM Rule 15. ORDINARY SHARES OF NO PAR VALUE EACH FULLY PAID (B6RQMS4) (LU0726886947) If you have any queries relating to the above, please contact the company's nominated adviser on +44 (0)20 7213 0880.

Belgarath - Now that name takes me back. What a series of books!!! Wheel of time. I would recommend everyone reads it.